What are the side effects of Tenvir 300 mg?
In the pharmaceutical industry, Tenvir 300 mg is a potent Nucleotide Reverse Transcriptase Inhibitor (NRTI). As a pharmacist and manufacturer, I view this molecule as a “Nucleotide Analog”—it is technically a prodrug of tenofovir, specifically engineered to improve oral bioavailability for the long-term management of HIV-1 infection and Chronic Hepatitis B (HBV).
At your WHO-GMP facility in Mumbai, Tenvir is a high-volume “Life-Saving” SKU. For your digital platforms, highlighting its “High Genetic Barrier to Resistance” is a major technical differentiator for international B2B tenders.
Therapeutic Profile: Side Effect Classification
Tenvir is generally well-tolerated, but its long-term use requires specific monitoring of renal and bone health.
| Side Effect | Clinical Frequency | Technical Rationale |
| Gastrointestinal | Common | Includes nausea, diarrhea, and flatulence; usually mild and resolves within the first few weeks. |
| Dizziness / Headache | Common | Central nervous system effects that are typically transient as the body adjusts to the medication. |
| Renal Impairment | Occasional/Serious | Can cause proximal renal tubulopathy (Fanconi syndrome), leading to increased serum creatinine. |
| Bone Density Loss | Occasional | Linked to a decrease in Bone Mineral Density (BMD), increasing the risk of osteomalacia or fractures. |
| Lactic Acidosis | Rare but Critical | A metabolic complication associated with NRTIs; requires immediate medical intervention. |
Mechanism: Chain Termination & Mitochondrial Impact
Tenvir works by “mimicking” the building blocks of viral DNA:
Prodrug Conversion: Tenofovir disoproxil fumarate is converted intracellularly to the active tenofovir diphosphate.
DNA Chain Termination: It competes with the natural substrate (deoxyadenosine 5′-triphosphate) for incorporation into viral DNA. Once incorporated, it lacks the necessary “hook” to add the next link, effectively stopping viral replication.
Renal Transporters: Technically, it is actively secreted by the kidneys via Organic Anion Transporters (OAT1/OAT3). Over-accumulation in these tubule cells is what leads to the characteristic renal side effects.
The Pharmacist’s “Technical Warning”
-
The “Renal” Monitor: As a pharmacist, I must emphasize that Creatinine Clearance (CrCl) must be calculated before starting Tenvir. If CrCl is below $50\text{ mL/min}$, the dosing interval must be adjusted (e.g., once every 48 hours).
-
HBV Flare-Up: Critical Safety Note: Patients co-infected with HIV and HBV who stop Tenvir abruptly may experience severe acute exacerbations of Hepatitis B. Treatment should never be discontinued without strict medical supervision.
-
Bone Health Support: For long-term patients, particularly those with a history of fractures, calcium and Vitamin D supplementation is technically recommended to mitigate BMD loss.
-
Fat Redistribution: Like other antiretrovirals, it may cause changes in body fat (lipodystrophy), though this is less common with tenofovir than with older NRTIs.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
-
The “Hepatitis B” USP: On your digital marketplace, position Tenvir 300 mg as the “Gold Standard for HBV.” Its high potency and low resistance rates make it a preferred first-line therapy for government liver-health tenders.
-
Stability for Export: Tenofovir is stable but highly sensitive to moisture, which can lead to the formation of “Tenofovir Monoester” impurities. Utilizing Alu-Alu blister packaging or induction-sealed HDPE bottles with desiccant is essential for a 36-month shelf life in Zone IVb regions.
-
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers to support your firm’s registration in international HIV/AIDS (PEPFAR/Global Fund) and Hepatitis B tenders.